Navigation Links
Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel

Worms, Germany (PRWEB) May 21, 2015

W. R. Grace & Co. (NYSE: GRA) announces that its manufacturing facility in Worms, Germany has received good manufacturing practice (GMP) certification from EXCiPACT™, an independent subsidiary of the International Pharmaceutical Excipient Council (IPEC) Foundation.

All three Grace facilities that produce its SYLOID® FP brand of pharmaceutical grade excipient silica gels have now received GMP certification, following the Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. The certification provides Grace customers an independent verification of quality, ensuring product safety while minimizing overall supply chain costs.

“This certification provides our customers with an extra level of certainty about the quality and standards used by our silica manufacturing facilities,” said Adam Grose, Vice President and General Manager of Grace Discovery Sciences. “GMP certification is increasingly important in pharmaceutical manufacturing to ensure the highest standards for safety and performance of all ingredients in drug production. Also, this certification removes an auditing requirement, which saves our customers time and money.”

Five years ago, Grace’s Curtis Bay facility received the first GMP certification ever issued from an IPEC-sanctioned audit, setting the standard for the industry.

EXCiPACT is a voluntary, self-regulated initiative of the global pharmaceutical excipient industry, supported by manufacturers, distributors, and pre-formulators. The organization ensures that cGMP and cGDP requirements are applied to pharmaceutical excipients through a recognized auditing and certification process, thereby increasing safety, reliability, and transparency of the supply chain. Certification ensures quality and efficacy in pharmaceutical excipients, promoting their best use in medicines as a means of improving patient treatment and safety.

For over 40 years, Grace has been manufacturing silica excipients for the pharmaceutical and related industries. More recently, there is a focus on drug delivery applications and utilizing mesoporous silica-based technology to enhance the oral bioavailability of poorly water-soluble active pharmaceutical ingredients.

Here is a link to download a high resolution version of the plant photo:

About Grace
Built on talent, technology, and trust, Grace is a leading global supplier of catalysts; engineered and packaging materials; and specialty construction chemicals and building materials. The company’s three industry-leading business segments—Grace Catalysts Technologies, Grace Materials Technologies, and Grace Construction Products—provide innovative products, technologies, and services that improve the products and processes of customer partners in over 155 countries around the world. Grace’s 2014 net sales were $3.2 billion. More information about Grace is available at

# # #

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Grace Century’s Portfolio Project Board Member Asked to Serve on Bahamian Pre-Clearance Stem Cell Ethics Committee
2. Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas
3. Dr. Yousef Siddiqui joins the Grace Century Advisory Team
4. Grace to Raise Prices for Silica Products Worldwide
5. Grace Launches New REVELERIS® Prep Purification System
6. Grace Century Attends Provia Labs First Quarter Expansion Meeting January 5-10
7. Grace Century, FZ LLC Publishes Annual Global and Regional Financial Predications for 2014
8. Dalia Dergham Joins Grace Century FZ LLC International Project Team
9. Grace Century Attends Provia Laboratories Cycle II Launch
10. Eddie Leong Signs on as Advisory Board Member and Compliance Officer for Grace Century, International Research and Private Equity Consultant
11. Bryan, Garnier & Co Announces the Successful $275m IPO for Galapagos NV, the Largest Nasdaq IPO of European Biotech
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):